Melinta Therapeutics

Melinta Therapeutics is an antibiotics-focused company.  The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.  The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Peter Piliero as Vice President of Medical Affairs, effective today. Dr. Piliero, an Infectious Disease specialist and global Medical Affairs leader, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller. In this role, Dr. Piliero will be responsibl

Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs

Acurx Pharmaceuticals LLC

Cidara Therapeutics

Iterum Therapeutics Plc

Nabriva Therapeutics

Paratek Pharma

SCYNEXIS

Summit Therapeutics

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021.

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta appoints Susan Blum as Chief Financial Officer

Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with ABSSSI.

Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics announces the appointment of Kristen Allgor as Chief Human Resources Officer.

Melinta Therapeutics Announces Appointment of Kristen Allgor as Chief Human Resources Officer

MORRISTOWN, N.J., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020.

Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer

MORRISTOWN, N.J., June  24, 2020  (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) dated as of June 4, 2020 (the “Merger Agreement”), it had terminated the previously announced cash tender offer to acquire all of the outstanding shares of common stock of Tetraphase (the “Offer”).

Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase

Company Enters Growth Phase in Hospital Market with Support of Deerfield

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals

Company Poised to Emerge on Financially Sound Footing Ensuring Continued Availability of Company’s Products and Related Support Company Poised to Emerge on Financially Sound Footing Ensuring Continued Availability of Company’s Products and Related Support

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company

Bids due on March 2, 2020 by 4:00 p.m. Eastern Time

Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures

Shares of biotech Melinta Therapeutics Inc. MLNT, -54.36% slid 59% Friday, after the developer of novel antibiotics to treat bacterial infections filed for chapter 11 bankruptcy protection.

Melinta Therapeutics stock slides after company files for chapter 11 bankruptcy protection

Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations

Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

Shares of Melinta Therapeutics Inc. MLNT, -42.50% plummeted 45% toward a record low to pace all premarket decliners Wednesday, after the commercial-stage drug maker included a "going concern" warning in its quarterly filing, for the third consecutive quarter.

Melinta Therapeutics stock plunges toward record low after another 'going concern' warning

Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 10.88% and 2.35%, respectively, for the quarter ended September 2019.

Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates

MORRISTOWN, N.J., Nov.  12, 2019  (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2019 with the Securities and Exchange Commission (“SEC”).

Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019

Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Melinta Therapeutics, Inc. (MLNT) Report Negative Q3 Earnings?

~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.

Implied Volatility Surging for Melinta Therapeutics (MLNT) Stock Options

MORRISTOWN, N.J., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta.

Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director

Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -19.46% and 13.96%, respectively, for the quarter ended June 2019.

Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Tops Revenue Estimates

Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower.

Is a Beat in Store for Melinta (MLNT) This Earnings Season?

Melinta Therapeutics, Inc. (MLNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Melinta Therapeutics, Inc. (MLNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Melinta Therapeutics, Inc. (MLNT) closed at $4.07 in the latest trading session, marking a -0.49% move from the prior day.

Melinta Therapeutics, Inc. (MLNT) Dips More Than Broader Markets: What You Should Know

Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter.

Melinta (MLNT) Announces Preliminary Product Sales for Q2

Atara Biotherapeutics

AvroBio Inc

Tuesday was a breakout day for a few biotech companies that saw solid gains. With the markets at all-time highs, these companies could help push things higher.

News for Melinta Therapeutics Stock (MLNT)